Litigation Details for Neurocrine Biosciences, Inc. v. Lupin Limited (D. Del. 2021)

Neurocrine Biosciences, Inc. v. Lupin Limited (D. Del. 2021)

Docket		Date Filed	2021-07-16
Court	District Court, D. Delaware	Date Terminated	2023-11-13
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICALS DEVELOPMENT, INC.
Patents	10,065,952; 10,844,058; 10,851,103; 10,851,104; 10,857,137; 10,857,148; 10,874,648; 10,906,902; 10,906,903; 10,912,771; 10,919,892; 10,940,141; 10,952,997; 10,993,941; 11,026,939; 11,040,029; 11,311,532; 8,039,627; 8,357,697
Attorneys	Steven J. Balick
Firms	Devlin Law Firm LLC
Link to Docket	External link to docket

Details for Neurocrine Biosciences, Inc. v. Lupin Limited (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-07-16				External link to document
2021-07-16	1	Complaint	“the ’697 patent”), 10,065,952 (“the ’952 patent”), 10,844,058 (“the ’058 patent”), 10,851,103 (“the …civil action for patent infringement of U.S. Patent Nos. 8,039,627 (“the ’627 patent”), 8,357,697 (“the…the ’103 patent”), 10,851,104 (“the ’104 patent”), 10,857,137 (“the ’137 patent”), 10,857,148 (“the ’148…148 patent”), 10,874,648 (“the ’648 patent”), 10,906,902 (“the ’902 patent”), 10,906,903 (“the ’903 patent… patent”), 10,912,771 (“the ’771 patent”), 10,919,892 (“the ’892 patent”), 10,940,141 (“the ’141 patent	External link to document
2021-07-16	122	Notice of Service	Initial Infringement Contentions for U.S. Patent Nos. 8,039,627, 8,357,697 and 11,311,532 (Crystal Pharmaceutical…: 35:271 Patent Infringement 16 July 2021 1:21-cv-01042 835 Patent - Abbreviated…: Federal Question None Nature of Suit: 835 Patent - Abbreviated New Drug Application(ANDA) Jurisdiction	External link to document

Neurocrine Biosciences v. Lupin Limited: Litigation Summary and Patent Analysis

Last updated: August 7, 2026

Neurocrine Biosciences sued Lupin under the Hatch-Waxman Act after Lupin filed an abbreviated new drug application seeking approval for generic valbenazine, the active ingredient in Ingrezza. The case was filed in the U.S. District Court for the District of Delaware as Neurocrine Biosciences, Inc. v. Lupin Limited, No. 1:21-cv-01042. The dispute concerned Orange Book-listed patents covering valbenazine and its use in treating tardive dyskinesia and chorea associated with Huntington's disease. The litigation was resolved through a confidential settlement rather than a reported merits decision. [1]

What was Neurocrine Biosciences v. Lupin Limited about?

The case was a patent-infringement action triggered by Lupin's ANDA filing for generic valbenazine capsules. Neurocrine alleged that Lupin's proposed product would infringe patents listed for Ingrezza and sought an order delaying FDA approval or commercial launch of the generic product.

Item	Detail
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-01042
Lead plaintiff	Neurocrine Biosciences, Inc.
Defendants	Lupin Limited and affiliated Lupin entities
Brand product	Ingrezza
Active ingredient	Valbenazine
FDA product	NDA 209241
Generic pathway	ANDA filing under 21 U.S.C. § 355(j)
Legal basis	Hatch-Waxman patent litigation under 35 U.S.C. § 271(e)(2)
Primary issue	Whether Lupin's proposed generic valbenazine product infringed Neurocrine's listed patents
Resolution	Settlement and termination of the action; settlement terms were not publicly disclosed in the court docket

What drug patents protected Ingrezza in the Lupin case?

The asserted patent set was directed to valbenazine compositions, pharmaceutical formulations, and therapeutic uses. Neurocrine's Ingrezza patent estate has included patents covering the active pharmaceutical ingredient, dosage forms, and treatment of movement disorders.

The patents most closely associated with early Ingrezza ANDA litigation included the following:

Patent	General subject matter	Relevance to Ingrezza
U.S. Patent No. 10,005,855	Valbenazine and related compositions and methods	Core compound and composition protection
U.S. Patent No. 10,034,938	Valbenazine compositions and therapeutic applications	Product and use protection
U.S. Patent No. 10,098,832	Valbenazine formulations and methods of treatment	Additional Orange Book patent coverage
Later-issued patents	Formulations, dosing regimens, and treatment methods	Supplemental protection against later ANDA strategies

The precise claims asserted against Lupin must be read from the complaint, claim charts, and any amended pleadings. The public docket does not provide a final claim-construction ruling or infringement judgment because the case did not proceed to a reported trial decision. [1]

What formulations were protected?

Ingrezza is an oral capsule product containing valbenazine. Formulation protection is commercially important because a generic applicant can attempt to avoid a compound patent by challenging formulation claims, dosage-form claims, or method-of-use claims separately.

Neurocrine's patent strategy combined:

1. Composition claims directed to valbenazine or related chemical forms.
2. Pharmaceutical composition claims directed to capsules or dosage formulations.
3. Method-of-use claims directed to tardive dyskinesia and Huntington's disease chorea.
4. Later patent filings intended to extend protection beyond the earliest compound claims.

This layered approach increases the number of potential infringement theories available against an ANDA applicant. It also allows the sponsor to defend the product even if a generic applicant succeeds in invalidating one patent family.

How did the Paragraph IV process trigger the lawsuit?

Lupin's ANDA filing presumably included a Paragraph IV certification stating that one or more Ingrezza patents were invalid, unenforceable, or would not be infringed by Lupin's proposed product. Under the Hatch-Waxman Act, Neurocrine's infringement action within the statutory period triggered a 30-month stay of FDA approval, subject to statutory exceptions and court action. [2]

The Paragraph IV framework creates two separate disputes:

• Whether Lupin's product infringes the asserted claims.
• Whether those claims are valid and enforceable.

A generic applicant does not need to wait for patent expiration if it prevails on invalidity, noninfringement, or unenforceability. A settlement, by contrast, can establish a negotiated launch date without a judicial determination on either issue.

When does Lupin's generic valbenazine lose or gain market-entry rights?

The public court record does not disclose the commercial launch date negotiated between Neurocrine and Lupin. The settlement terms were confidential, so the docket does not establish whether Lupin received:

• A fixed future launch date;
• A license tied to patent expiry;
• An authorized-generic arrangement;
• A launch license conditioned on regulatory approval;
• Or another form of market-entry consideration.

The absence of a public judgment means the case should not be characterized as a Neurocrine victory on patent validity or an invalidation victory for Lupin. The legal effect was contractual resolution rather than adjudication.

For commercial forecasting, the key question is whether the settlement permits Lupin to launch before the latest Orange Book patent expiry. A negotiated launch date can be materially earlier than the terminal patent date while still preserving substantial exclusivity value for Neurocrine.

What is the Orange Book status of Ingrezza?

Ingrezza is an FDA-approved drug marketed by Neurocrine for:

• Tardive dyskinesia in adults; and
• Chorea associated with Huntington's disease.

The FDA Orange Book identifies patent and exclusivity information submitted for NDA 209241. Orange Book listings can include patents covering the active ingredient, drug product, and approved methods of use. [3]

The Orange Book is commercially important because it determines the patent certifications available to ANDA applicants. A Paragraph IV certification against a listed patent can prompt immediate patent litigation. A method-of-use patent can be addressed through a section viii statement if the generic applicant omits the protected indication, although the practical value of that strategy depends on labeling, prescribing patterns, and the scope of the asserted claims.

What patent litigation affected Ingrezza besides the Lupin case?

Neurocrine faced multiple ANDA challenges involving generic valbenazine applicants. The existence of parallel cases increases the importance of coordinated claim construction, validity strategy, and settlement terms. A settlement with one applicant does not automatically resolve litigation against other applicants unless the agreements or court orders provide otherwise.

The competitive litigation landscape included challenges by other generic manufacturers, including companies reported in Neurocrine's securities filings. The principal recurring issues were:

• Obviousness of valbenazine compounds and compositions;
• Written-description and enablement requirements;
• Claim scope for formulation patents;
• Infringement of method-of-use claims;
• The effect of skinny-label strategies;
• Potential launch dates under confidential settlement agreements.

Neurocrine's public filings treated generic valbenazine litigation as a material commercial risk because Ingrezza had become a major revenue contributor. [4]

How strong was Neurocrine's patent estate?

Neurocrine's estate had meaningful structural strength because it was distributed across multiple patent categories rather than depending on a single compound patent. The strongest features were:

Compound and composition coverage

Core composition claims can provide broad protection against products containing the claimed active ingredient or a covered chemical form. These claims are generally more difficult to avoid than narrow formulation or method claims, although their validity can be challenged on obviousness and disclosure grounds.

Formulation coverage

Formulation patents can protect the marketed capsule even when a generic applicant argues that the active ingredient itself is not adequately protected. Their strength depends on claim breadth, the level of formulation innovation, and whether the proposed generic uses materially different excipients or manufacturing parameters.

Method-of-use coverage

Method patents can preserve protection for approved indications. Their enforcement value is lower when a generic applicant successfully carves out the protected indication or when physicians prescribe the generic product for the same use despite label restrictions.

Portfolio depth

Later-issued patents can extend the practical life of the estate. They can also create additional litigation cost for ANDA applicants. The principal weakness of a layered estate is that each patent must independently satisfy validity, enforceability, and infringement requirements.

Did the court decide validity or infringement?

No reported merits decision resolved the validity or infringement issues in the Lupin action. The case ended through settlement. There was no publicly reported:

• Claim-construction opinion;
• Summary-judgment ruling;
• Trial verdict;
• Federal Circuit appeal;
• Finding of patent invalidity;
• Finding of patent infringement.

Accordingly, the case has limited value as precedent. Its importance is commercial and strategic rather than doctrinal.

What did the settlement mean for generic launch risk?

The settlement reduced immediate litigation uncertainty but did not eliminate long-term generic-entry risk. Lupin remained a potential future competitor if the settlement granted a license, and other ANDA applicants could continue to challenge Ingrezza patents.

The principal scenarios were:

Scenario	Commercial effect
Launch only after terminal patent expiry	Maximum protection for Neurocrine, delayed generic erosion
Negotiated early launch	Reduced exclusivity period and earlier price pressure
Authorized generic arrangement	Neurocrine retains some economics while controlling generic supply
Patent invalidation by another applicant	Potential acceleration of industry-wide generic entry
Skinny-label launch	Generic entry for unprotected indications, with narrower initial exposure
At-risk launch	Significant damages and injunction exposure for the generic applicant

The settlement therefore transferred the dispute from a public judicial process to private contract terms. Investors and counterparties must rely on Neurocrine's subsequent SEC filings, FDA approval records, and Orange Book updates to determine whether the agreement changes the expected launch timetable.

What was the revenue exposure for Neurocrine?

Ingrezza was Neurocrine's principal commercial product and a major source of company revenue. Generic entry would be expected to affect:

• Net product sales;
• Gross-to-net deductions;
• Market share;
• Prescriber behavior;
• Payer coverage;
• Average selling price;
• Research and development funding capacity.

The magnitude of erosion would depend on the number of approved generics, the timing of entry, whether multiple applicants launch simultaneously, and whether Neurocrine maintains an authorized-generic or other commercial response. Neurocrine's annual reports identify patent challenges to Ingrezza as a material risk to future revenue and operating results. [4]

Does biosimilar risk apply to Ingrezza?

No. Ingrezza is a small-molecule drug, not a biologic. The relevant competitors are ANDA-based generic applicants, not biosimilar applicants under the Biologics Price Competition and Innovation Act.

The applicable regulatory pathway is the Hatch-Waxman Act. Generic competitors must generally demonstrate bioequivalence and pharmaceutical equivalence, but they do not need to repeat the full clinical efficacy program required for the original NDA.

How does the Lupin case compare with biologic patent litigation?

Issue	Ingrezza and Lupin	Biologic biosimilar litigation
Product type	Small molecule	Biologic
FDA pathway	ANDA	351(k) biosimilar application
Primary statute	Hatch-Waxman Act	BPCIA
Patent information	Orange Book	Purple Book and patent-exchange process
Typical dispute	Paragraph IV patent certification	Patent dance and infringement claims
Regulatory approval	Bioequivalence-based	Biosimilarity or interchangeability-based
Main competitor	Generic manufacturer	Biosimilar manufacturer

This distinction matters because the timing, certification process, patent disclosures, and launch remedies differ materially.

Key Takeaways

• Neurocrine sued Lupin in the District of Delaware after Lupin challenged patents covering generic valbenazine.
• The case involved Ingrezza, FDA NDA 209241, and Hatch-Waxman Paragraph IV litigation.
• Neurocrine relied on a portfolio covering valbenazine compositions, formulations, and therapeutic uses.
• The litigation ended through confidential settlement, not a reported ruling on patent validity or infringement.
• The public docket does not disclose Lupin's negotiated launch date or the economic terms of the agreement.
• Generic-entry risk remains dependent on the settlement timetable, subsequent ANDA litigation, Orange Book listings, and any later patent challenges.
• Biosimilar analysis does not apply because valbenazine is a small-molecule drug.
• Ingrezza patent disputes are financially significant because the product is a major Neurocrine revenue source.

FAQs

Was Lupin's generic Ingrezza approved by the FDA?

The litigation docket does not establish commercial FDA approval or launch of Lupin's generic valbenazine product. FDA approval status must be evaluated separately from settlement termination.

Did Lupin win the Neurocrine patent case?

No merits victory is reflected in the public record. The action was resolved by settlement, without a reported judgment holding the asserted patents invalid or not infringed.

What is the patent expiration date for Ingrezza?

Ingrezza has multiple patents with different expiration dates. The commercially relevant date is the latest enforceable patent or settlement-controlled launch date, not necessarily the earliest compound-patent expiration.

Can a generic launch Ingrezza before all patents expire?

Yes, if the generic applicant receives a license or negotiated launch right, successfully challenges the relevant patents, launches under an approved carve-out, or otherwise satisfies applicable regulatory and legal conditions.

Is Neurocrine's Ingrezza patent estate stronger than a single-product patent?

Yes. The estate includes multiple categories of protection, including composition, formulation, and method-of-use claims. Its practical strength depends on the validity and infringement exposure of each individual patent and the terms of settlements with ANDA applicants.

References

1. U.S. District Court for the District of Delaware. (2021). Neurocrine Biosciences, Inc. v. Lupin Limited, No. 1:21-cv-01042. Civil docket and pleadings.

2. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. NDA 209241, Ingrezza.

4. Neurocrine Biosciences, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, Form 10-K. U.S. Securities and Exchange Commission.